ID   NB69
AC   CVCL_1448
SY   NB-69; NB_69; NB 69; NB69-RIKEN
DR   BTO; BTO:0005426
DR   CLO; CLO_0050263
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 951
DR   BioSample; SAMN03470996
DR   cancercelllines; CVCL_1448
DR   Cell_Model_Passport; SIDM00244
DR   ChEMBL-Cells; CHEMBL3308799
DR   ChEMBL-Targets; CHEMBL1075510
DR   Cosmic; 688081
DR   Cosmic; 801739
DR   Cosmic; 908440
DR   Cosmic; 920248
DR   Cosmic; 930069
DR   Cosmic; 947709
DR   Cosmic; 1019930
DR   Cosmic; 1037342
DR   Cosmic; 1099139
DR   Cosmic; 1109123
DR   Cosmic; 1153787
DR   Cosmic; 1890119
DR   Cosmic; 2058110
DR   Cosmic; 2131577
DR   Cosmic-CLP; 908440
DR   DepMap; ACH-002083
DR   ECACC; 99072802
DR   EGA; EGAS00001000978
DR   GDSC; 908440
DR   GEO; GSM313807
DR   GEO; GSM563353
DR   GEO; GSM827391
DR   GEO; GSM1670154
DR   GEO; GSM2371245
DR   GEO; GSM2394385
DR   GEO; GSM3145725
DR   GEO; GSM4104585
DR   GEO; GSM4104586
DR   GEO; GSM4104632
DR   GEO; GSM4104633
DR   GEO; GSM4104634
DR   GEO; GSM4105323
DR   GEO; GSM4105324
DR   GEO; GSM4105325
DR   GEO; GSM4105326
DR   GEO; GSM4105327
DR   IARC_TP53; 21531
DR   IARC_TP53; 27184
DR   LINCS_LDP; LCL-1999
DR   PharmacoDB; NB69_993_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1448
DR   PubChem_Cell_line; CVCL_1448
DR   RCB; RCB0480
DR   Wikidata; Q54907543
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   PubMed=16822308;
RX   PubMed=18923524;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=23202128;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=28350380;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Chromatin accessibility by ATAC-seq.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K27me3 ChIP-seq epigenome analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.26%; East Asian, North=0.67%; East Asian, South=0%; South Asian=0.54%; European, North=64.54%; European, South=34% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; ECACC; PubMed=25877200; RCB
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 8
ST   D16S539: 9,11
ST   D18S51: 15,16
ST   D19S433: 14,15
ST   D21S11: 30.2,31.2,32
ST   D2S1338: 17,23
ST   D3S1358: 16,17
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 13.2,14,15
ST   FGA: 21,25
ST   Penta D: 7,12
ST   Penta E: 10,13
ST   TH01: 8
ST   TPOX: 8,11 (Cosmic-CLP; PubMed=25877200; RCB)
ST   TPOX: 11 (ECACC)
ST   vWA: 17,18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   1Y4M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=18923524; DOI=10.1038/nature07399;
RA   Chen Y.-Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M.,
RA   Wang L.-L., Soda M., Kikuchi A., Igarashi T., Nakagawara A.,
RA   Hayashi Y., Mano H., Ogawa S.;
RT   "Oncogenic mutations of ALK kinase in neuroblastoma.";
RL   Nature 455:971-974(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=23202128; DOI=10.1038/ng.2493;
RA   Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y.,
RA   Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.;
RT   "Integrated genomic analyses identify ARID1A and ARID1B alterations in
RT   the childhood cancer neuroblastoma.";
RL   Nat. Genet. 45:12-17(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//